Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Obesity Medicine
Can procalcitonin be used as a marker for endothelial dysfunction emanating from chronic inflammation of obesity?
Related Questions
Why is it recommended to switch to a non-oral contraceptive or add a barrier method of contraception for 4 weeks after tirzepatide initiation but not with semaglutide?
What vitamins and minerals do you check yearly for patients post gastric bypass surgery?
Are you more likely to recommend medical management for obesity instead of bariatric surgery in patients with preexisting hypothyroidism, given a recent study showing increased risks of complications?
In patients with severe obesity, do you recommend a trial of GLP 1 R agonist therapy prior to bariatric surgery?
Can fatty liver disease present with elevations in alkaline phosphatase without other liver enzyme elevations (AST and ALT)?
In patients with iron deficiency due to history of gastric bypass or IBD, would you consider oral iron therapy if the iron deficiency anemia is mild?
Should orlistat be avoided in patients with a history of kidney stones?
What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?
Do you recommend restarting GLP-1RA after bariatric surgery if they tolerated it before the surgery?
How do you decide between bariatric surgery and a GLP-1 receptor agonist for patients with metabolic dysfunction-associated steatotic liver disease who have not met weight loss goals after six months of lifestyle interventions?
